Moderna raises $2 billion after Phase 3 success of its algorithm-driven personalized cancer vaccine with Merck

Moderna announced a $2 billion convertible debt financing, a move that follows the Phase 3 success of its personalized cancer vaccine developed with Merck.

The vaccine relies on software that scans thousands of tumor mutations and selects 34 neoantigens to encode into a bespoke mRNA formulation, a computational approach that could define the treatment's effectiveness.

If approved, the therapy would be the first medicine whose genetic instructions are generated by an algorithm, marking a novel regulatory and scientific milestone, though some researchers remain cautious.

The newsletter also noted a recent heart‑drug failure, RevMed’s pancreatic cancer drug gaining approval, and a China biotech crackdown that may benefit European firms.